Skip to main navigationSkip to main content
The University of Southampton
Medicine
Phone:
(023) 8120 6671
Email:
M.D.Blunt@soton.ac.uk

Dr Matthew Blunt BSc, PhD

Research Fellow, Postdoctoral Career Track Award Fellow

Dr Matthew Blunt's photo

Dr Matthew Blunt is a Research Fellow and a Postdoctoral Career Track Award Fellow within the Faculty of Medicine.

I completed a PhD in immunology and pharmacology at the University of Bath in 2013, funded by the BBSRC and Novartis. I subsequently joined the Cancer Sciences Unit at the University of Southampton to study novel treatment strategies for hematological malignancies with Dr Andrew Steele. For this work I was awarded the Catovsky prize (2014) by the UK CLL forum and the John Marsden Prize (2015 and 2016) by the University of Southampton.  

 

I subsequently moved to the laboratory of Professor Salim Khakoo in 2017 to study natural killer cells and cancer immunotherapies. In 2018 I was awarded the Postdoctoral Career Track Award by the University of Southampton.

Qualifications

BSc, Biological Sciences, University of Reading  (2009)

PhD, University of Bath  (2013)

Appointments held

Faculty of Medicine Postdoctoral Career Track Award Fellow       2018- Present

Research Fellow, Clinical and Experimental Sciences Unit, University of Southampton   2017- Present

Research Fellow, Cancer Sciences Unit, University of Southampton     2013-2017

Research interests

I studied novel treatment strategies for B cell malignancies at the University of Southampton with Dr Andrew Steele from 2013 to 2017. Projects included:

Targeting the PI3K/mTOR pathway in CLL (Blunt MD et al, Blood, 2015).

Identification of IL-4 as a resistance mechanism to idelalisib and ibrutinib (*Aguilar-Hernandez M, *Blunt MD et al, Blood, 2016 *Co-first author).

Preclinical evaluation of the dual SYK/JAK inhibitor cerdulatinib alone and in combination with venetoclax (Blunt MD et al, Clin Cancer Res, 2016).

I subsequently moved to the laboratory of Professor Salim Khakoo in 2017 to study natural killer cells and cancer immunotherapies. This work aims to understand how peptides control NK cell activation and how this can be utilized therapeutically. To date, this work has resulted in the development of a novel method to assess KIR2DS2 positive NK cells (Blunt et al, HLA, 2019).

Research group

Clinical and Experimental Sciences

Faculty of Medicine
Member of the Faculty of Medicine Patent Panel

Sort via:TypeorYear

Articles

Letter/Editorial

 

Supervision of the laboratory work of PhD, BMedSc, BSc and MSc students in the research group of Dr Andrew Steele 

Facilitated Pathological Mechanisms of Disease

 

 

Dr Matthew Blunt
Cancer Sciences Unit
Somers Cancer Research Building
Southampton General Hospital (MP824)
Tremona Road
Southampton SO16 6YD

Room Number: SGH/LE 68/MP811

Share this profile Share this on Facebook Share this on Twitter Share this on Weibo
Privacy Settings